SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-028321
Filing Date
2022-03-01
Accepted
2022-03-01 06:46:48
Documents
13
Period of Report
2022-02-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm227900d1_8k.htm   iXBRL 8-K 38011
2 EXHIBIT 99.1 tm227900d1_ex99-1.htm EX-99.1 19369
  Complete submission text file 0001104659-22-028321.txt   236483

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA acur-20220228.xsd EX-101.SCH 3039
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE acur-20220228_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acur-20220228_pre.xml EX-101.PRE 22599
7 EXTRACTED XBRL INSTANCE DOCUMENT tm227900d1_8k_htm.xml XML 3502
Mailing Address 616 N. NORTH COURT, SUITE 120 . PALATINE IL 60067
Business Address 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067 847-705-7709
ACURA PHARMACEUTICALS, INC (Filer) CIK: 0000786947 (see all company filings)

IRS No.: 110853640 | State of Incorp.: NY | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-10113 | Film No.: 22693870
SIC: 2834 Pharmaceutical Preparations